BACKGROUND: Treatments for obsessive-compulsive disorder (OCD) usually lead to incomplete symptom relief and take a long-time to reach full effect. Convergent evidence suggests that glutamate abnormalities contribute to the pathogenesis of OCD. Ketamine is a potent noncompetitive antagonist of the N-methyl-D-aspartate glutamate receptor. Trials have reported rapid antidepressant effects after low-dose ketamine infusion. METHODS: We conducted an open-label trial of ketamine (.5 mg/kg IV over 40 min) in 10 subjects with treatment-refractory OCD. Response was defined as >35% improvement in OCD symptoms and >50% improvement in depression symptoms from baseline at any time between 1 and 3 days after infusion. RESULTS: None of 10 subjects experienced a response in OCD symptoms in the first 3 days after ketamine. Four of seven patients with comorbid depression experienced an antidepressant response to ketamine in the first 3 days after infusion. Both OCD and depression symptoms demonstrated a statistically significant improvement in the first 3 days after infusion compared with baseline, but the OCD response was <12%. The percentage reduction in depressive symptoms in the first 3 days after ketamine infusion was significantly greater than the reduction in OCD symptoms. CONCLUSIONS: Ketamine effects on OCD symptoms, in contrast to depressive symptoms, did not seem to persist or progress after the acute effects of ketamine had dissipated.
BACKGROUND: Treatments for obsessive-compulsive disorder (OCD) usually lead to incomplete symptom relief and take a long-time to reach full effect. Convergent evidence suggests that glutamate abnormalities contribute to the pathogenesis of OCD. Ketamine is a potent noncompetitive antagonist of the N-methyl-D-aspartateglutamate receptor. Trials have reported rapid antidepressant effects after low-dose ketamine infusion. METHODS: We conducted an open-label trial of ketamine (.5 mg/kg IV over 40 min) in 10 subjects with treatment-refractory OCD. Response was defined as >35% improvement in OCD symptoms and >50% improvement in depression symptoms from baseline at any time between 1 and 3 days after infusion. RESULTS: None of 10 subjects experienced a response in OCD symptoms in the first 3 days after ketamine. Four of seven patients with comorbid depression experienced an antidepressant response to ketamine in the first 3 days after infusion. Both OCD and depression symptoms demonstrated a statistically significant improvement in the first 3 days after infusion compared with baseline, but the OCD response was <12%. The percentage reduction in depressive symptoms in the first 3 days after ketamine infusion was significantly greater than the reduction in OCD symptoms. CONCLUSIONS:Ketamine effects on OCD symptoms, in contrast to depressive symptoms, did not seem to persist or progress after the acute effects of ketamine had dissipated.
Authors: R M Berman; A Cappiello; A Anand; D A Oren; G R Heninger; D S Charney; J H Krystal Journal: Biol Psychiatry Date: 2000-02-15 Impact factor: 13.382
Authors: D R Rosenberg; F P MacMaster; M S Keshavan; K D Fitzgerald; C M Stewart; G J Moore Journal: J Am Acad Child Adolesc Psychiatry Date: 2000-09 Impact factor: 8.829
Authors: David R Rosenberg; Yousha Mirza; Aileen Russell; Jennifer Tang; Janet M Smith; S Preeya Banerjee; Rashmi Bhandari; Michelle Rose; Jennifer Ivey; Courtney Boyd; Gregory J Moore Journal: J Am Acad Child Adolesc Psychiatry Date: 2004-09 Impact factor: 8.829
Authors: Mark J Niciu; Ioline D Henter; David A Luckenbaugh; Carlos A Zarate; Dennis S Charney Journal: Annu Rev Pharmacol Toxicol Date: 2014 Impact factor: 13.820
Authors: Summer L Thompson; Amanda C Welch; Julia Iourinets; Stephanie C Dulawa Journal: Psychopharmacology (Berl) Date: 2020-01-11 Impact factor: 4.530
Authors: Jerome H Taylor; Angeli Landeros-Weisenberger; Catherine Coughlin; Jilian Mulqueen; Jessica A Johnson; Daniel Gabriel; Margot O Reed; Ewgeni Jakubovski; Michael H Bloch Journal: Neuropsychopharmacology Date: 2017-08-29 Impact factor: 7.853
Authors: Dennis L Murphy; Pablo R Moya; Meredith A Fox; Liza M Rubenstein; Jens R Wendland; Kiara R Timpano Journal: Philos Trans R Soc Lond B Biol Sci Date: 2013-02-25 Impact factor: 6.237
Authors: Christopher Pittenger; Michael H Bloch; Suzanne Wasylink; Eileen Billingslea; Ryan Simpson; Ewgeni Jakubovski; Ben Kelmendi; Gerard Sanacora; Vladimir Coric Journal: J Clin Psychiatry Date: 2015-08 Impact factor: 4.384
Authors: Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker Journal: BMC Psychiatry Date: 2014-07-02 Impact factor: 3.630